Intellipharmaceutics (IPCI) Reports Q2 Loss of $0.08/Share

Intellipharmaceutics (NASDAQ: IPCI) reported Q2 EPS of ($0.08), versus ($0.06) reported last year. Revenue for the quarter came in at $600 thousand, versus $1.3 million reported last year.

For earnings history and earnings-related data on Intellipharmaceutics (IPCI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'
• Benchmark Reiterates Speculative Buy Rating on Nephros (NEPH) Following Strong Q2 Results